A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes

Inclusion Criteria: * Healthy subjects * Body mass index (BMI) of 18.5-30 kg/m\^2 (both incl.) Exclusion Criteria: * History of or presence of cancer, diabetes, pancreatitis or any clinically relevant cardiovascular diseases or other major disorders * Use of prescription or non-prescription medicinal products (except routine vitamins, acetylsalicylic acid and paracetamol) within 3 weeks (or within 5 half-lives of the medicinal product, whichever is longest) prior to the first dosing of semaglutide * Smoking, drug or alcohol abuse * Female of childbearing potential who is pregnant, breast-feeding or intend to become pregnant or not using adequate contraceptive methods for the duration of the trial and for 3 months following the last dose of semaglutide